{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.7","upperLimit":"67.6","value":"51.1"},{"groupId":"OG001","lowerLimit":"13.7","upperLimit":"46.6","value":"29.2"},{"groupId":"OG002","lowerLimit":"23.0","upperLimit":"60.7","value":"42.5"},{"groupId":"OG003","lowerLimit":"15.8","upperLimit":"39.9","value":"27.2"},{"groupId":"OG004","lowerLimit":"30.6","upperLimit":"71.0","value":"52.9"},{"groupId":"OG005","lowerLimit":"57.1","upperLimit":"89.3","value":"77.8"},{"groupId":"OG006","lowerLimit":"16.2","upperLimit":"54.6","value":"35.0"},{"groupId":"OG007","lowerLimit":"9.0","upperLimit":"65.4","value":"36.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"68"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"30"},{"groupId":"OG006","value":"30"},{"groupId":"OG007","value":"11"}],"units":"Participants"}],"description":"Overall survival at one-year is defined as the percentage of participants who were alive one year after receiving their first dose of study drug.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with NSCLC with no prior exposure to any PD-1 pathway targeting drug (PD-1 naïve) received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG000","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: NSCLC (PD-1 Naïve)"},{"description":"Participants with NSCLC with de novo or acquired resistance to an anti-PD-1 targeting drug (PD-1 resistant) received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG001","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: NSCLC (PD-1 Resistant)"},{"description":"Participants with SCCHN received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG002","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: SCCHN"},{"description":"Participants with pancreatic cancer received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG003","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Pancreatic Cancer"},{"description":"Participants with advanced ovarian cancer received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG004","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Ovarian Cancer"},{"description":"Participants with RCC received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG005","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: RCC"},{"description":"Participants with malignant glioma received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG006","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: GBM"},{"description":"Participants with melanoma received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG007","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Melanoma"}],"paramType":"NUMBER","populationDescription":"All treated participants in Phase 1b; Efficacy endpoints were specified to be analyzed by disease type for phase 1b participants only.","reportingStatus":"POSTED","timeFrame":"52 weeks","title":"Efficacy: Overall Survival (OS) at One Year (Phase 1b)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}